Ali A Alattar1, Jiri Bartek2, Veronica L Chiang3, Alireza M Mohammadi4, Gene H Barnett4, Andrew Sloan5, Clark C Chen6. 1. School of Medicine, University of California San Diego, La Jolla, California, USA. 2. Department of Neurosurgery, Karolinska University Hospital, Stockholm, Sweden; Department of Clinical Neuroscience and Medicine, Karolinska Institutet, Stockholm, Sweden; Department of Neurosurgery, Rigshospitalet, Copenhagen, Denmark. 3. Department of Neurosurgery, Yale Medical School, New Haven, Connecticut, USA. 4. Department of Neurosurgery, Cleveland Clinic & Case Comprehensive Cancer Center, Cleveland, Ohio, USA. 5. Department of Neurosurgery, University Hospitals of Cleveland, Siedman Cancer Center, Cleveland, Ohio, USA; Case Comprehensive Cancer Center, Case Western Reserve University School of Medicine, Cleveland, Ohio, USA. 6. Department of Neurosurgery, University of Minnesota, Minneapolis, Minnesota, USA. Electronic address: ccchen@umn.edu.
Abstract
BACKGROUND: The optimal treatment of brain metastases recurring after radiosurgery (BMRS) remains an area of active investigation. Stereotactic laser ablation (SLA, also known as laser interstitial thermal therapy) has recently emerged as a potential treatment option. OBJECTIVE: To summarize the available literature on SLA as treatment of BMRS and synthesize findings on local control, overall survival, neurologic outcome, imaging findings, morbidity, and postprocedure clinical course. METHODS: We performed a comprehensive search of PubMed for articles investigating SLA as treatment of BMRS. RESULTS: Thirteen peer-reviewed publications met our search criteria. Local control was a function of the percentage of tumor that was thermally ablated. In completely ablated tumors, 3-month local control was 80%-100%. Median survival ranged from 5.8 to 19.8 months. About two-thirds of treated lesions showed postablation expansion of contrast-enhancing volume and fluid-attenuated inversion recovery volume. Expansion could start within an hour of treatment, and resolution typically occurred within 6 months. Notably, maximal expanded contrast-enhancing volume could reach >3-fold the preoperative lesion volume. The incidence of SLA-related permanent neurologic injuries was <10%. The most common complications were hemorrhage, thermal injury causing neurologic deficit, and malignant cerebral edema. Nearly all patients were treated with dexamethasone, but there was variability in the dose and duration of therapy. Median hospital stay was 1-2 days (range, 1-5 days), and most treated patients were discharged home (range, 59.5%-100%). CONCLUSION: Our analysis provides support for continued development of SLA as a treatment of BMRS. Standardization of periprocedural management will be needed.
BACKGROUND: The optimal treatment of brain metastases recurring after radiosurgery (BMRS) remains an area of active investigation. Stereotactic laser ablation (SLA, also known as laser interstitial thermal therapy) has recently emerged as a potential treatment option. OBJECTIVE: To summarize the available literature on SLA as treatment of BMRS and synthesize findings on local control, overall survival, neurologic outcome, imaging findings, morbidity, and postprocedure clinical course. METHODS: We performed a comprehensive search of PubMed for articles investigating SLA as treatment of BMRS. RESULTS: Thirteen peer-reviewed publications met our search criteria. Local control was a function of the percentage of tumor that was thermally ablated. In completely ablated tumors, 3-month local control was 80%-100%. Median survival ranged from 5.8 to 19.8 months. About two-thirds of treated lesions showed postablation expansion of contrast-enhancing volume and fluid-attenuated inversion recovery volume. Expansion could start within an hour of treatment, and resolution typically occurred within 6 months. Notably, maximal expanded contrast-enhancing volume could reach >3-fold the preoperative lesion volume. The incidence of SLA-related permanent neurologic injuries was <10%. The most common complications were hemorrhage, thermal injury causing neurologic deficit, and malignant cerebral edema. Nearly all patients were treated with dexamethasone, but there was variability in the dose and duration of therapy. Median hospital stay was 1-2 days (range, 1-5 days), and most treated patients were discharged home (range, 59.5%-100%). CONCLUSION: Our analysis provides support for continued development of SLA as a treatment of BMRS. Standardization of periprocedural management will be needed.
Authors: H Petra Kok; Erik N K Cressman; Wim Ceelen; Christopher L Brace; Robert Ivkov; Holger Grüll; Gail Ter Haar; Peter Wust; Johannes Crezee Journal: Int J Hyperthermia Date: 2020 Impact factor: 3.914
Authors: Isabela Peña Pino; Jun Ma; Yusuke S Hori; Elena Fomchenko; Kathryn Dusenbery; Margaret Reynolds; Christopher Wilke; Jianling Yuan; Ethan Srinivasan; Matthew Grabowski; Peter Fecci; Evidio Domingo-Musibay; Naomi Fujioka; Gene H Barnett; Veronica Chang; Alireza M Mohammadi; Clark C Chen Journal: J Neurooncol Date: 2022-01-10 Impact factor: 4.130
Authors: Truong H Do; Madeleine A Howard; Elise F Palzer; Jared D Huling; Mohammed A Alvi; Samuel W Cramer; Ping Zhu; Reid A Johnson; James Jean; Jinci Lu; Alec B Jonason; Jacob Hanson; Luke Sabal; Kevin W Sun; Robert A McGovern; Clark C Chen Journal: J Neurooncol Date: 2022-07-23 Impact factor: 4.506
Authors: Georgios P Skandalakis; Daniel R Rivera; Caroline D Rizea; Alexandros Bouras; Joe Gerald Jesu Raj; Dominique Bozec; Constantinos G Hadjipanayis Journal: Int J Hyperthermia Date: 2020-07 Impact factor: 3.914
Authors: Eduardo E Lovo; Leonel B Torres; Fidel J Campos; Victor E Caceros; Kaory E Barahona; Mario H Minervini; William A Reyes Journal: Cureus Date: 2019-08-24
Authors: Ilaria Viozzi; Alis Guberinic; Christiaan G Overduin; Maroeska M Rovers; Mark Ter Laan Journal: J Clin Med Date: 2021-01-19 Impact factor: 4.241
Authors: Birra R Taha; Christian R Osswald; Matthew Rabon; Carolina Sandoval Garcia; Daniel J Guillaume; Xiao Wong; Andrew S Venteicher; David P Darrow; Michael C Park; Robert A McGovern; Cornelius H Lam; Clark C Chen Journal: World Neurosurg X Date: 2021-12-16
Authors: Martin A Proescholdt; Petra Schödel; Christian Doenitz; Tobias Pukrop; Julius Höhne; Nils Ole Schmidt; Karl-Michael Schebesch Journal: Cancers (Basel) Date: 2021-03-31 Impact factor: 6.639
Authors: Elsa V Arocho-Quinones; Sean M Lew; Michael H Handler; Zulma Tovar-Spinoza; Matthew Smyth; Robert Bollo; David Donahue; M Scott Perry; Michael L Levy; David Gonda; Francesco T Mangano; Phillip B Storm; Angela V Price; Daniel E Couture; Chima Oluigbo; Ann-Christine Duhaime; Gene H Barnett; Carrie R Muh; Michael D Sather; Aria Fallah; Anthony C Wang; Sanjiv Bhatia; Kadam Patel; Sergey Tarima; Sarah Graber; Sean Huckins; Daniel M Hafez; Kavelin Rumalla; Laurie Bailey; Sabrina Shandley; Ashton Roach; Erin Alexander; Wendy Jenkins; Deki Tsering; George Price; Antonio Meola; Wendi Evanoff; Eric M Thompson; Nicholas Brandmeir Journal: J Neurosurg Pediatr Date: 2020-03-27 Impact factor: 2.375